

ASX Market Announcement

Appendix 3Y – Change of Director’s Interest Notice

Melbourne, Australia, 2 February 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, lodges the attached Appendix 3Y - Change of Director’s Interest Notice - for Dr George Muchnicki.

In relation to the attached Appendix 3Y, we advise:

- Dr Muchnicki’s American Depositary Receipts were sold by the holding agent without his prior knowledge during a trading blackout period pending the release of the Company’s half-year financial report. Dr Muchnicki was unaware that a W-8BEN form, Certificate of Foreign Status of Beneficial Owner for United States Tax Withholding and Reporting (Individuals), was required to be completed and returned to the holding agent resulting in the agent selling his shares.
- Dr Muchnicki remains the second largest individual shareholder in the company with the share sale occurring in one of his subsidiary entities.
- the Company’s directors are fully aware of its obligations under ASX Listing Rule 3.19A, requiring the Company to notify the ASX within 5 business days when there is a change in the notifiable interest of a director in the securities of GTG. Dr Muchnicki immediately notified the directors and company secretary of the sale of ADS when he became aware – 1 February 2023.
- as Dr Muchnicki was unaware that the sale of ADS was about to take place, he did not obtain the permission of the Chairman to trade as required by the Company’s Securities Trading Policy.
- the directors of GTG have agreed to review all holding arrangements of their securities held in GTG to ensure that this type of trade does not re-occur in the future.
- the Board of GTG can confirm that the Company is aware of its continuous disclosure obligations under listing rule 3.1.

<end>

Authorised for release by the board of directors of Genetic Technologies Limited.

Tony Di Pietro
CFO and Company Secretary

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company’s Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals. Leading the world in risk prediction in Oncology, Cardiovascular and Metabolic diseases. Genetic Technologies continues to develop a pipeline of risk assessment products. For more information, please visit www.genetype.com

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: GTG Technologies Limited
ABN: 17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jerzy Muchnicki
Date of last notice	9 November 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	MJGD Nominees Pty Ltd
Date of change	30 January 2023
No. of securities held prior to change	MJGD Nominees Pty Ltd 210,436,756 ordinary shares 38,400,000 ordinary shares (represented by 64,000 American Depositary Receipts) JGM Investment Group (The Muchnicki Family A/C) 9,400,000 ordinary shares MJGD Nominees Pty Ltd <BSMI A/C> 4,849,129 ordinary shares 7,500,000 Class A Performance Rights 25,000,000 Class B Performance Rights 25,000,000 Class C Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	Ordinary shares (represented by American Depositary Receipts)
Number acquired	Nil
Number disposed	38,400,000 ordinary shares (represented by 64,000 American Depositary Receipts)
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	US\$55,898.88 or US\$0.873420 per American Depositary Receipt (equivalent to A\$0.002 per ordinary share)
No. of securities held after change	<p>MJGD Nominees Pty Ltd 210,436,756 ordinary shares</p> <p>JGM Investment Group (The Muchnicki Family A/C) 9,400,000 ordinary shares</p> <p>MJGD Nominees Pty Ltd <BSMI A/C> 4,849,129 ordinary shares</p> <p>7,500,000 Class A Performance Rights 25,000,000 Class B Performance Rights 25,000,000 Class C Performance Rights</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On Market Trade – Dr Muchnicki's American Depositary Receipts were sold by the holding agent without his prior knowledge. Dr Muchnicki was unaware that a W-8BEN form - Certificate of Foreign Status of Beneficial Owner for United States Tax Withholding and Reporting (Individuals) was required to be completed and returned to the holding agent resulting in the agent selling his shares.

Part 2 – Change of director's interests in contracts

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	No
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.